Immunogenicity and protective efficacy of tuberculosis DNA vaccines combining mycolyl‐transferase Ag85A and phosphate transport receptor PstS‐3
- 26 May 2006
- journal article
- research article
- Published by Wiley in Immunology
- Vol. 118 (3) , 321-332
- https://doi.org/10.1111/j.1365-2567.2006.02373.x
Abstract
DNA vaccines encoding the 32,000 MW mycolyl-transferase Ag85A and the 40,000 MW phosphate-binding protein PstS-3 can elicit protective immune responses against experimental infection with Mycobacterium tuberculosis in C57BL/6 mice. Here we have analysed the vaccine potential of a combination of both antigens using plasmid vectors expressing either a fusion protein of both antigens or the separate proteins driven by two independent promoters (in pBudCE4.1 vector). Comparable levels of Ag85A specific T helper 1 (Th1) type immune responses could be induced by the two combination vaccines and the single vaccine encoding the mycolyl-transferase, whereas induction of PstS-3 specific Th1-mediated responses was impaired in both combination vaccines. In contrast, magnitude of CD8+ mediated responses against the PstS-3 protein was comparable following combination or single DNA vaccination. Antigenic competition was also observed at the antibody level; PstS-3 specific levels being lower in mice vaccinated with the fusion vector and Ag85A specific levels being lower in mice vaccinated with the combination pBudCE4.1 vector (as compared to levels obtained following single plasmid immunization). Protection against M. tuberculosis was only modestly improved in mice vaccinated with the DNA combinations. It is possible that prior activation of Ag85A specific CD4+ T cells directed against this common mycobacterial antigen leads to cross-competition for major histocompatibility complex class II-restricted peptide complexes of the Pst-3 antigen. This may have implications for future combination vaccines using Ag85.Keywords
This publication has 75 references indexed in Scilit:
- Priming but not boosting with plasmid DNA encoding mycolyl-transferase Ag85A from Mycobacterium tuberculosis increases the survival time of Mycobacterium bovis BCG vaccinated mice against low dose intravenous challenge with M. tuberculosis H37RvVaccine, 2006
- Evaluation of the immunogenicity of pBudCE4.1 plasmids encoding mycolyl-transferase Ag85A and phosphate transport receptor PstS-3 from Mycobacterium tuberculosisVaccine, 2005
- DNA vaccination for the priming of neutralizing antibodies against non-immunogenic STa enterotoxin from enterotoxigenic Escherichia coliVaccine, 2005
- Protective effect of DNA vaccine during chemotherapy on reactivation and reinfection of Mycobacterium tuberculosisGene Therapy, 2005
- How Soon after Infection with HIV Does the Risk of Tuberculosis Start to Increase? A Retrospective Cohort Study in South African Gold MinersThe Journal of Infectious Diseases, 2005
- Protection of macaques against Mycobacterium tuberculosis infection by a subunit vaccine based on a fusion protein of antigen 85B and ESAT-6Vaccine, 2004
- CD4+ T cells cross‐compete for MHC class II‐restricted peptide antigen complexes on the surface of antigen presenting cellsImmunology & Cell Biology, 2004
- Immunology of TuberculosisAnnual Review of Immunology, 2001
- Identification of a second Mycobacterium tuberculosis gene cluster encoding proteins of an ABC phosphate transporterFEBS Letters, 1996
- T cell response to purified filtrate antigen 85 from Mycobacterium bovis Bacilli Calmette-Guerin (BCG) in leprosy patientsClinical and Experimental Immunology, 1991